EA
EPZM

Emerald Advisers’s Epizyme, Inc EPZM Stock Holding History

Emerald Advisers’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,100
Closed -$290K – 386
2015
Q1 		$290K Sell
15,100
-480,900
-97% -$9.93M 0.01% 308
2014
Q4 		$9.36M Buy
496,000
+226,118
+84% +$5.28M 0.5% 71
2014
Q3 		$7.32M Sell
269,882
-10,300
-4% -$320K 0.43% 79
2014
Q2 		$8.72M Sell
280,182
-570
-0.2% -$13.4K 0.49% 67
2014
Q1 		$6.39M Buy
+280,752
New +$8.51M 0.36% 100
2013
Q3 		– Sell
-100,569
Closed -$2.83M – 362
2013
Q2 		$2.83M Buy
+100,569
New +$2.58M 0.17% 159

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Emerald Advisers's EPZM Position: Q2 2015 in Review

Emerald Advisers sold out of Epizyme, Inc (EPZM) in Q2 2015, closing a stake of 15,100 shares — an estimated $290K sold.

Emerald Advisers first reported a position in EPZM in Q2 2013 and held it in 6 quarters. The position peaked at $9.36M in Q4 2014. 95 funds tracked by Wall St. Rank hold EPZM as of Q2 2015.

  • Emerald Advisers reported no remaining Epizyme, Inc position as of Q2 2015 after selling out during the quarter.
  • Emerald Advisers sold 15,100 Epizyme, Inc shares in Q2 2015, an estimated $290K.
  • Emerald Advisers first reported a position in Epizyme, Inc in Q2 2013 and held it in 6 quarters.
  • Emerald Advisers's Epizyme, Inc position peaked at $9.36M in Q4 2014.
  • 95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2015.

Based on Emerald Advisers's 13F filing for Q2 2015, filed 28 Jul 2015.